Literature DB >> 16991128

Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s.

Matti Lehtinen1, Marjo Kaasila, Kari Pasanen, Toni Patama, Johanna Palmroth, Päivi Laukkanen, Eero Pukkala, Pentti Koskela.   

Abstract

Vaccines against high-risk (hr) human papillomaviruses (HPVs) causing cervical cancer may soon be licensed. Thus, nature of HPV epidemics needs to be studied now. Random sampling for studies on HPV epidemiology was done from all 230,998 women belonging to the population-based Finnish Maternity Cohort and having a minimum of 2 pregnancies between 1983 and 1994. First pregnancy serum specimens were retrieved for 7,805 subjects, and were analyzed for antibodies to HPV6/11, 16 and 18 with standard ELISAs. HPV16 seroprevalence almost doubled from the 1980s to the 1990s, and the epidemic spread to new areas in 23-31 year olds, i.e. the bulk of pregnant female population in the southwest part of the country. The HPV16 epidemic in the 14-22 year olds in 1983-1988 (1961-1974 birth cohorts) and in the 23-31 year olds in 1989-1994 (1958-1971 birth cohorts) overlapped with strong clustering of HPV16 and HPV18 infections in the latter (odds ratio 8.0, 95% confidence interval 6.6-9.7). Similar clustering of HPV16 and HPV6/11 infections was not found. The epidemic and the clustering may be due to high transmission probability of the hrHPV types and increase in sexual activity of the index birth cohorts.

Entities:  

Mesh:

Year:  2006        PMID: 16991128     DOI: 10.1002/ijc.22131

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

Review 1.  Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review.

Authors:  Sarah M Tiggelaar; Margaret J Lin; Raphael P Viscidi; Jia Ji; Jennifer S Smith
Journal:  J Adolesc Health       Date:  2012-02       Impact factor: 5.012

2.  Seroprevalences of herpes simplex virus type 2, five oncogenic human papillomaviruses, and Chlamydia trachomatis in Katowice, Poland.

Authors:  Staffan Görander; Teresa Lagergård; Malgorzata Romanik; Raphael P Viscidi; Gayane Martirosian; Jan-Ake Liljeqvist
Journal:  Clin Vaccine Immunol       Date:  2008-02-20

Review 3.  Clinical trials of human papillomavirus vaccines and beyond.

Authors:  Matti Lehtinen; Joakim Dillner
Journal:  Nat Rev Clin Oncol       Date:  2013-06-04       Impact factor: 66.675

4.  Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers.

Authors:  Anil K Chaturvedi; William F Anderson; Joannie Lortet-Tieulent; Maria Paula Curado; Jacques Ferlay; Silvia Franceschi; Philip S Rosenberg; Freddie Bray; Maura L Gillison
Journal:  J Clin Oncol       Date:  2013-11-18       Impact factor: 44.544

5.  Low avidity of human papillomavirus (HPV) type 16 antibodies is associated with increased risk of low-risk but not high-risk HPV type prevalence.

Authors:  Proscovia B Namujju; Lea Hedman; Klaus Hedman; Cecily Banura; Edward K Mbidde; Dennison Kizito; Romano N Byaruhanga; Moses Muwanga; Reinhard Kirnbauer; Heljä-Marja Surcel; Matti Lehtinen
Journal:  BMC Res Notes       Date:  2011-06-06

6.  Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland.

Authors:  K M French; R V Barnabas; M Lehtinen; O Kontula; E Pukkala; J Dillner; G P Garnett
Journal:  Br J Cancer       Date:  2007-01-23       Impact factor: 7.640

Review 7.  Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes.

Authors:  David Mesher; Kate Soldan; Matti Lehtinen; Simon Beddows; Marc Brisson; Julia M L Brotherton; Eric P F Chow; Teresa Cummings; Mélanie Drolet; Christopher K Fairley; Suzanne M Garland; Jessica A Kahn; Kimberley Kavanagh; Lauri Markowitz; Kevin G Pollock; Anna Söderlund-Strand; Pam Sonnenberg; Sepehr N Tabrizi; Clare Tanton; Elizabeth Unger; Sara L Thomas
Journal:  Emerg Infect Dis       Date:  2016-10       Impact factor: 6.883

8.  Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses.

Authors:  Marc Arbyn; Sara B Smith; Sarah Temin; Farhana Sultana; Philip Castle
Journal:  BMJ       Date:  2018-12-05

9.  Seroprevalence of mucosal and cutaneous human papillomavirus (HPV) types among children and adolescents in the general population in Germany.

Authors:  Anna Loenenbach; Michael Pawlita; Tim Waterboer; Thomas Harder; Christina Poethko-Müller; Michael Thamm; Raskit Lachmann; Yvonne Deleré; Ole Wichmann; Miriam Wiese-Posselt
Journal:  BMC Infect Dis       Date:  2022-01-10       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.